CD44 and breast neoplasm: Treatment of CD44+/CD24− BCSCs derived from breast tumor tissues with formestane, an aromatase inhibitor, results in a 16% (p < 0.01) decrease in cell proliferation in response to single-agent trastuzumab and 50% decrease (p < 0.001) in response to combined trastuzumab and formestane treatment.